HLB Pharmaceutical Co., Ltd (047920.KQ)

KRW 23050.0

(-1.5%)

Market Cap (In KRW)

733.32 Billion

Revenue (In KRW)

135.95 Billion

Net Income (In KRW)

-19.42 Billion

Avg. Volume

934.66 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
12880.0-42050.0
PE
-
EPS
-
Beta Value
1.831
ISIN
KR7047920004
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Jae-hyeong Park
Employee Count
-
Website
https://www.hlbpharma.co.kr
Ipo Date
2015-12-21
Details
HLB Pharmaceutical Co., Ltd, a pharmaceutical company, researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxants, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease. It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services. The company was formerly known as Mediforum Pharmaceutical Incorporation and changed its name to HLB Pharmaceutical Co., Ltd in October 2020. HLB Pharmaceutical Co., Ltd was founded in 1998 and is headquartered in Namyangju-Si, South Korea.